Relapsed, Refractory Malignant Neoplasms

1 clinical trials · Condition

Record	Firm	Date
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (NCT04730349)	Bristol-Myers Squibb	2021-06-03

Every clearance here is in the API, with alerts when new ones post.